281 related articles for article (PubMed ID: 32321715)
1. AMPK Activation by Metformin Promotes Survival of Dormant ER
Hampsch RA; Wells JD; Traphagen NA; McCleery CF; Fields JL; Shee K; Dillon LM; Pooler DB; Lewis LD; Demidenko E; Huang YH; Marotti JD; Goen AE; Kinlaw WB; Miller TW
Clin Cancer Res; 2020 Jul; 26(14):3707-3719. PubMed ID: 32321715
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.
Hadad SM; Hardie DG; Appleyard V; Thompson AM
Clin Transl Oncol; 2014 Aug; 16(8):746-52. PubMed ID: 24338509
[TBL] [Abstract][Full Text] [Related]
3. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
Ma J; Guo Y; Chen S; Zhong C; Xue Y; Zhang Y; Lai X; Wei Y; Yu S; Zhang J; Liu W
BMC Cancer; 2014 Mar; 14():172. PubMed ID: 24612549
[TBL] [Abstract][Full Text] [Related]
4. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
Zou J; Hong L; Luo C; Li Z; Zhu Y; Huang T; Zhang Y; Yuan H; Hu Y; Wen T; Zhuang W; Cai B; Zhang X; Huang J; Cheng J
Cancer Sci; 2016 Dec; 107(12):1806-1817. PubMed ID: 27636742
[TBL] [Abstract][Full Text] [Related]
6. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.
Brown KA; Hunger NI; Docanto M; Simpson ER
Breast Cancer Res Treat; 2010 Sep; 123(2):591-6. PubMed ID: 20300828
[TBL] [Abstract][Full Text] [Related]
7. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
8. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
[TBL] [Abstract][Full Text] [Related]
9. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
10. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment.
Daurio NA; Tuttle SW; Worth AJ; Song EY; Davis JM; Snyder NW; Blair IA; Koumenis C
Cancer Res; 2016 Jun; 76(11):3295-306. PubMed ID: 27020861
[TBL] [Abstract][Full Text] [Related]
11. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Wang Y; Wei J; Li L; Fan C; Sun Y
Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
[TBL] [Abstract][Full Text] [Related]
12. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
13. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
[TBL] [Abstract][Full Text] [Related]
14. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
15. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
16. Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Liu B; Fan Z; Edgerton SM; Deng XS; Alimova IN; Lind SE; Thor AD
Cell Cycle; 2009 Jul; 8(13):2031-40. PubMed ID: 19440038
[TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche.
Han HH; Kim BG; Lee JH; Kang S; Kim JE; Cho NH
Endocr Relat Cancer; 2016 Aug; 23(8):609-23. PubMed ID: 27353038
[TBL] [Abstract][Full Text] [Related]
18. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
20. Metformin in breast cancer: preclinical and clinical evidence.
De A; Kuppusamy G
Curr Probl Cancer; 2020 Feb; 44(1):100488. PubMed ID: 31235186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
